Labelled compounds as radiopharmaceuticals for radiosynoviorthesis

Abstract

Radiopharmaceuticals for radiosynoviorthesis are designed as suspension (colloidal) of particles in sterile and pyrogen free form, where radionuclide (active substance) fix on carrier which is form solid particles or gel form. Generally, radionuclide and carrier have to fulfil the request of sterility, chemical purity, non toxicity, non allergen and low cost preparation. In term of the radionuclide purity, beta-emission with sufficient energy for penetration and ablation the synovial tissue and low gamma-radiation is requested. The radionuclide gold-198 in colloidal form was used as radiopharmaceutical for radiosynoviorthesis at first. Presently, beta-emitting radionuclides, which have no or only a minimal gammaemission, are used. Between such radionuclides is possible to insert: yttrium-90, rhenium-186 and radiolanthanoides — dysprosium-165, holmium-166 and erbium-169. In this paper are presented experiences with preparation [¹⁶⁶Ho] Holmium-Macroaggregates ([¹⁶⁶Ho] holmium-MA), [¹⁶⁶Ho] holmium-Polylactic Acid Microspheres ([¹⁶⁶Ho] Ho-PLA-MS) which are potential candidate for radiosynoviorhesis.